Literature DB >> 27888630

The association of variants in PNPLA3 and GRP78 and the risk of developing hepatocellular carcinoma in an Italian population.

Daniele Balasus1, Michael Way2, Caterina Fusilli3, Tommaso Mazza3, Marsha Y Morgan2, Melchiorre Cervello4, Lydia Giannitrapani1, Maurizio Soresi1, Rosalia Agliastro5, Manlio Vinciguerra2,6, Giuseppe Montalto1,4.   

Abstract

Hepatocellular carcinoma (HCC) has one of the worst prognoses amongst all malignancies. It commonly arises in patients with established liver disease and the diagnosis often occurs at an advanced stage. Genetic variations, such as single nucleotide polymorphisms (SNPs), may alter disease risk and thus may have use as predictive markers of disease outcome. The aims of this study were (i) to assess the association of two SNPs, rs430397 in GRP78 and rs738409 in PNPLA3 with the risk of developing HCC in a Sicilian association cohort and, (ii) to use a machine learning technique to establish a predictive combinatorial phenotypic model for HCC including rs430397 and rs738409 genotypes and clinical and laboratory attributes. The controls comprised of 304 healthy subjects while the cases comprised of 170 HCC patients the majority of whom had hepatitis C (HCV)-related cirrhosis. Significant associations were identified between the risk of developing HCC and both rs430397 (p=0.0095) and rs738409 (p=0.0063). The association between rs738409 and HCC was significantly stronger in the HCV positive cases. In the best prediction model, represented graphically by a decision tree with an acceptable misclassification rate of 17.0%, the A/A and G/A genotypes of the rs430397 variant were fixed and combined with the three rs738409 genotypes; the attributes were age, sex and alcohol. These results demonstrate significant associations between both rs430397 and rs738409 and HCC development in a Sicilian cohort. The combinatorial predictive model developed to include these genetic variants may, if validated in independent cohorts, allow for earlier diagnosis of HCC.

Entities:  

Keywords:  genetic variants; hepatitis C virus; hepatocellular carcinoma; risk factors; single nucleotide polymorphisms

Mesh:

Substances:

Year:  2016        PMID: 27888630      PMCID: PMC5349954          DOI: 10.18632/oncotarget.13558

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

Hepatocellular carcinoma (HCC) is the most common of the primary liver cancers. It is the fifth most common malignancy worldwide and the third most frequent cause of cancer-related deaths [1-3]. The epidemiology of HCC is complex reflecting, to a large extent, differences in levels of exposure to known predisposing factors such as the presence of cirrhosis, chronic infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) and environmental toxin exposure. Prevalence rates are 16 to 32 times higher in economically less- developed countries such as sub-Saharan Africa South-east Asia and China [4]. In Eastern Asia the major risk factor for HCC is infection with hepatitis B [5, 6], whereas in Northern and Western Europe excess alcohol consumption and infection with HCV are the main antecedents [3]. In developed countries HCC develops most frequently in patients with established cirrhosis whereas elsewhere HCC may arise in patients with chronic HBV and HCV infection at a pre-cirrhotic stage [7, 8]. There are also data to support a role for tobacco smoking, diabetes and obesity as risk factors or risk co-factors for the development of HCC [9]. Finally there are important gender differences in HCC prevalence; men are at two- to five-fold increased risk of developing this malignancy than women, depending on geographic area, which most likely reflect their increased exposures to known risk factors [1]. As the epidemiology of HCC has become better understood, so has the fact that only 5 to 20% of the populations potentially at risk actually develop HCC. Interest has, therefore, turned to the identification of the factors responsible for the differences in individual susceptibility; in particular the role of genetic variation. Two of the most notable genetic findings to date have been the association between the Single Nucleotide Polymorphisms (SNP), rs430397 and rs738409, with HCC risk. The rs430397 variant in glucose regulated protein 78 (GRP78 also known as HSPA5) has been associated with HCC and cirrhosis risk in Chinese populations with HBV infection [10, 11]. There is considerable functional and genetic evidence implicating the GRP78 protein in mechanisms of HCC carcinogenesis [12, 13] and indeed in malignancies at other sites [14, 15]. The rs738409 variant in patatin-like phospholipase domain-containing 3 (PNPLA3) has been identified as conferring a significant risk for developing cirrhosis in relation to non-alcohol-related fatty liver disease [16] and alcohol-related liver disease [17]. The rs738409 variant not only contributes to liver injury, but also to the risk of development of subsequent HCC [18, 19]. The nature of the association between the rs738409 variant in HCV-related HCC is less well characterized than in HCC of other aetiologies possibly because there is significant heterogeneity in the study populations in which this variant has been studied [20]. Variants in GRP78 and PNPLA3 have been associated with HCC risk in populations of diverse ancestry and with HCC of diverse aetiology. It is not known, however what proportion of the variance in HCC risk can be attributed to genetic factors in Southern European populations in whom the main risk factor for the development of HCC is chronic HCV infection and the incidence is rising [9]. Further, it is widely recognized that HCC risk prediction in chronic liver disease will have clinical utility in guiding evidence-based decisions about patient management [21] but it is unclear as to whether genetic information could improve the predictive models. Machine learning techniques have the potential to improve the accuracy of predictive models using genetic data [22]. A number of machine learning techniques have been developed, but all make use of computer algorithms that improve predictive accuracy with experience. Decision tree algorithms in particular are a well-established technique, which are useful for exploratory analysis and model visualisation. The aims of the present study were therefore to assess, whether (i) two genetic variants in PNPLA3 and GRP78 are associated with the risk of developing HCC in a Sicilian population, and (ii) whether inclusion of genotypic information would contribute to a predictive model designed to stratify patients by HCC risk.

RESULTS

Cohort characteristics

The cases were significantly older than the healthy controls (mean ± 1SD age 70.2± 8.0 vs. 56.6 ± 8.1 years; p = 2.2 × 10-16) and comprised of proportionately fewer men (70.4% vs. 58.2%, p = 0.007) (Table 1). All but one of the cases had established cirrhosis; in the majority chronic HCV infection was the aetiological agent (Table 1). A small proportion of patients (n=12; 7%), had marked steatosis in addition to cirrhosis. Up to 40% of the cases had experienced a major complication of chronic liver disease; and the majority had features of hepatocellular dysfunction with poor synthetic and excretory function (Table 2). Features of cirrhosis were evident on imaging in all included cases; ultrasonography was the modality most frequently employed (Table 2). The diagnosis of HCC was made in the majority on the basis of multimodal imaging; less than a quarter of patients had an elevated serum alpha-fetoprotein level (Table 3).
Table 1

Characteristics of the healthy controls and HCC cases included in the genetic association study

VariableControls (n=304)HCC cases (n=170)
Age at diagnosis (yr)56.6 ± 8.170.2 ± 8.0
Gender
 Men214 (70.4)99 (58.2)
 Women90 (29.6)71 (41.8)
Aetiology of Liver Disease
 HCV144 (84.7)
 Alcohol10 (5.9)
 Cryptogenic10 (5.9)
 HBV9 (5.3)
 Dysmetabolic syndrome1 (0.6)

Data are mean ± 1SD or number (%)

Abbreviations: HCV- hepatitis C virus; HBV- hepatitis B virus.

Table 2

Historical, clinical, laboratory, imaging and histological information used to diagnosis cirrhosis in the HCC cases

Variables used to diagnose cirrhosisCases (n=170)
History and clinical findingsAffected/abnormal n (%)
Variceal hemorrhage66 (38.8)
Ascites44 (25.9)
Hepatic encephalopathy10 (5.9)
Laboratory investigations
Thrombocytopaenia*137 (80.6)
Prolonged prothrombin time*53 (31.2)
Hypoalbuminaemia*13 (7.6)
Hyperbilirubinaemia*11 (6.5)
Investigations including imaging
Ultrasound163 (95.9)
CT-Scan8 (4.7)
Endoscopy5 (2.9)
Histology20 (11.8)

* Laboratory cut-off values: platelet count: < 150 × 109/L, Prothrombin time > 40 sec, plasma albumin < 35 g/L, serum bilirubin > 1.2 mg/dl.

Table 3

Laboratory, imaging and histological information used to diagnose HCC

Variables used to diagnose cirrhosisCases (n=170)
Laboratory InvestigationsAffected/abnormal n (%)
Elevated serum alpha-fetoprotein*37 (21.8)
Imaging
CT-Scan146 (85.9)
Ultrasound27 (15.9)
MRI-Scan27 (15.9)
Histology20 (11.8)

* Laboratory cut-off values: serum alpha-fetoprotein > 400 ng/ml.

Data are mean ± 1SD or number (%) Abbreviations: HCV- hepatitis C virus; HBV- hepatitis B virus. * Laboratory cut-off values: platelet count: < 150 × 109/L, Prothrombin time > 40 sec, plasma albumin < 35 g/L, serum bilirubin > 1.2 mg/dl. * Laboratory cut-off values: serum alpha-fetoprotein > 400 ng/ml.

Genotyping quality

The genotyping success rate was greater than 95% for both variants, with genotype distributions showing no evidence for deviation from Hardy-Weinberg equilibrium in controls (p >0.05). The minor and major allele designations of both rs430397 and rs738409 were generally similar in this Sicilian ancestry cohort to those in reference Europeans ancestry groups [23]; however, the minor allele (G) of rs738409 was noticeably more frequent in Sicilian controls than in European reference populations.

GRP78 and PNPLA3 polymorphisms and HCC

Both rs430397 in GRP78 and rs738409 in PNPLA3 were significantly associated with HCC risk in this Sicilian ancestry cohort (Table 4). The association between rs430397 in GRP78 and HCC risk is best described by a dominant model (AA+AG vs. GG), (p= 0.0095, OR= 1.81) whereas the association between rs738409 in PNPLA3 is best described by a recessive model (GG vs. CG +CC), (p= 6.28×10-3, OR= 2.56) (Table 5).
Table 4

Allelic associations between the SNPs rs430397 and rs738409 in sicilian cases with HCC and healthy controls

Gene (SNP)GroupnMinor AlleleGenotype CountsMAFCases vs Controls
Significance pOR (95% CI)
AAAGGG
GRP78(rs430397)Cases170A1461230.1410.0161.65(1.09-2.50)
Controls3042512510.090
GGCGCC
PNPLA3(rs738409)Cases170G3564710.394.22×10-31.50 (1.14-1.98)
Controls304281281480.30

Abbreviations: SNP – Single nucleotide polymorphism; n – number; MAF – Minor allele frequency; OR: Odds ratio; CI: Confidence Interval.

Table 5

Associations between rs430397 and rs738409 genotypes in sicilian cases with HCC and healthy controls using different genetic models

Gene (SNP)ModelEntire cohort (n=474)Entire cohort excluding non HCV-related cases (n=448)
POR95% CIPOR95% CI
Allelic0.0141.711.11-2.630.03481.641.04-2.58
GRP78(rs430397)Dominant0.00951.811.16-2.830.01901.761.10-2.82
Recessive0.930.890.08-9.93---
Allelic0.00651.451.11-1.900.003631.521.15-2.02
PNPLA3(rs738409)Dominant0.151.320.91-1.930.1271.370.92-2.04
Recessive0.00632.561.49-4.382.41×10-32.821.62-4.90

Abbreviations: SNP – Single nucleotide polymorphism; OR: Odds ratio; CI: Confidence Interval.

Abbreviations: SNP – Single nucleotide polymorphism; n – number; MAF – Minor allele frequency; OR: Odds ratio; CI: Confidence Interval. Abbreviations: SNP – Single nucleotide polymorphism; OR: Odds ratio; CI: Confidence Interval. When the analyses were confined to cases with HCC related to chronic HCV infection there was no evidence of association between rs430397 in GRP78 and HCC risk (Table 5). Because the frequency of the rs430397: AA genotype in this stratified cohort was very low, an association test under a recessive model of inheritance (AA vs. AG+GG) could not be performed using logistic regression. In contrast, the magnitude of the association between rs738409 in PNPLA3 and HCC risk increased when confined to the HCV positive HCC cases (p=2.41×10-3, OR=2.82) (Table 5). There was no evidence for an epistatic interaction between the two variants and HCC risk (Pasymptotic = 0.8, ORinteraction = 1.08). None of the demographic, clinical, laboratory or diagnostic variables was associated with either the GRP78 or PNPLA3 genotypes (Table 6).
Table 6

Association between rs430397 and rs738409 and demographic, clinical and laboratory variables in the HCC cases

Characteristicsrs430397rs738409
A/A + G/A (n=47)G/G (n=123)pC/C (n=71)C/G (n=64)G/G (n=35)p (C/C vs C/G)p (C/C vs G/G)
Age (years):
<7121 (44.7%)59 (48%)35 (49.3%)31 (48.4%)14 (40%)0.9420.4867
>=7126 (55.3%)64 (52%)0.83236 (50.7%)33 (51.6%)21 (60%)
Gender:
M23 (48.9%)76 (61.8%)44 (62%)38 (59.4%)17 (48.6%)0.8950.270
F24 (51.1%)47 (38.2%)0.17827 (38%)26 (40.6%)18 (51.4%)
HCV:
Yes39 (83%)105 (85.4%)59 (83.1%)53 (82.8%)32 (91.4%)0.8530.389
No8 (17%)18 (14.6%)0.88212 (16.9%)11 (17.2%)3 (8.6%)
HBV:
Yes3 (6.4%)6 (4.9%)5 (7%)3 (4.7%)1 (2.9%)0.8310.667
No44 (93.6%)117 (95.1%)0.99366 (93%)61 (95.3%)34 (97.1%)
Alcohol:
Yes3 (6.4%)7 (5.7%)4 (5.6%)6 (9.4%)0 (0%)0.6170.374
No44 (27.5%)116 (94.3%)0.84767 (94.4%)58 (90.6%)35 (100%)
Cirrhosis:
Yes47 (100%)122 (99.2%)71 (100%)64 (100%)34 (97.1%)0.6060.717
No0 (0%)1 (0.8%)0.6160 (0%)0 (0%)1 (2.9%)
Cryptogenic:
Yes4 (8.5%)6 (4.9%)4 (5.6%)4 (6.2%)2 (5.7%)0.8310.667
No43 (91.5%)117 (95.1%)0.59267 (94.4%)60 (93.7%)33 (94.3%)
Dysmetabolic:
Yes0 (0%)1 (0.8%)0 (0%)1 (1.6%)0 (0%)0.9587.00×10-3
No47 (100%)122 (99.2%)0.61671 (100%)63 (98.4%)35(100%)
Ascites:
Yes11 (23.4%)33 (26.8%)22 (31%)12 (18.8%)10 (28.6%)0.9580.976
No36 (76.6%)90 (73.2%)0.79549 (69%)52 (81.2%)25 (71.4%)
Variceal hemorrhage:
Yes16 (34%)50 (40.7%)28 (39.4%)19 (29.7%)19 (54.3%)0.3140.215
No31 (66%)73 (59.3%)0.53943 (60.6%)45 (70.3%)16 (45.7%)
Hepatic encephalopathy:
Yes1 (2.1%)9 (7.3%)6 (8.5%)2 (3.1%)2 (5.7%)0.3450.912
No46 (97.9%)114 (92.7%)0.35765 (91.5%)62 (96.9%)33 (94.3%)
Thrombocytopaenia:
Yes42 (89.4%)95 (77.2%)55 (77.5%)52 (81.5%)30 (85.7%)0.7420.458
No5 (10.6%)28 (22.8%)0.11616 (22.5%)12 (18.8%)5 (14.3%)
Prolonged prothrombin time
Yes16 (34%)37 (30.1%)23 (32.4%)20 (31.2%)10 (28.6%)0.9660.860
No31 (66%)86 (69.9%)0.75448 (67.6%)44 (68.7%)25 (71.4%)
Hyperbilirubinaemia
Yes5 (10.6%)6 (4.9%)3 (4.2%)5 (7.8%)3 (8.6%)0.6060.643
No42 (89.4%)117 (95.1%)0.30968 (95.8%)59 (92.2%)32 (91.4%)
Hypoalbuminaemia
Yes4 (8.4%)9 (7.3%)4 (5.6%)7 (10.9%)2 (5.7%)0.4180.667
No43 (91.5%)114 (92.7%)0.95267 (94.4%)57 (89.1%)33 (94.3%)
Raised serum alphafetoprotein
Yes8 (17%)29 (23.6%)0.47216 (22.5%)16 (25%)5 (14.3%)0.8940.458
No39 (83%)94 (76.4%)55 (77.5%)48 (75%)30 (85.7%)

Modelling of phenotypes and PNPLA3/GRP78 polymorphisms in the HCC cases

The first decision tree included different combinations of rs430397 and rs738409 genotypes, and the attributes of: age, sex, HCV status, ascites, variceal haemorrhage, prolonged prothrombin time and elevated serum alpha-fetoprotein (Figure 1). This decision tree had a misclassification rate (MCR) of 40%.
Figure 1

Decision tree based on the genotypes of both PNPLA3 and GRP78 SNPs

In this analysis the included discriminating attributes were: age, sex, HCV status, ascites, variceal haemorrhage, prolonged prothrombin time (PTT), elevated serum alpha-fetoprotein (AFP). The first genotype refers to the rs430397 variant and the second, separated by “-”, refers to the rs738409 variant. The ratio of the genotypes accurately classified over those wrongly classified is provided for each genotype in brackets.

Decision tree based on the genotypes of both PNPLA3 and GRP78 SNPs

In this analysis the included discriminating attributes were: age, sex, HCV status, ascites, variceal haemorrhage, prolonged prothrombin time (PTT), elevated serum alpha-fetoprotein (AFP). The first genotype refers to the rs430397 variant and the second, separated by “-”, refers to the rs738409 variant. The ratio of the genotypes accurately classified over those wrongly classified is provided for each genotype in brackets. The second decision tree included only three possible genotypic combinations: the rs430397 G/G was fixed and combined with the three rs738409 genotypes; the discriminating attributes were age, sex, HBV status, steatosis, ascites, variceal haemorrhage, thrombocytopenia, prolonged prothrombin time, elevated serum alpha-fetoprotein (Figure 2). The predictive power of this decision tree substantially improved resulting in a MCR of 24.4%.
Figure 2

Decision tree developed fixing the rs430397 G/G genotype

In this analysis, the most discriminating attributes were: age, sex, HBV, steatosis, ascites, variceal haemorrhage, thrombocytopenia, prolonged prothrombin time (PTT), elevated serum alpha-fetoprotein (AFP). The genotype in the box refers to rs738409. The ratio of the genotypes accurately classified over those wrongly classified is provided for each genotype in brackets.

Decision tree developed fixing the rs430397 G/G genotype

In this analysis, the most discriminating attributes were: age, sex, HBV, steatosis, ascites, variceal haemorrhage, thrombocytopenia, prolonged prothrombin time (PTT), elevated serum alpha-fetoprotein (AFP). The genotype in the box refers to rs738409. The ratio of the genotypes accurately classified over those wrongly classified is provided for each genotype in brackets. The third decision tree, which was complimentary to the second, kept only A/A and G/A genotypes of the rs430397 variant and the discriminating attributes: age, sex and alcohol. This was the most discriminating of the decision trees with a MCR of 17.0% (Figure 3).
Figure 3

Decision tree developed fixing the rs430397 A/A and G/A genotypes

This analysis selected the age, sex and alcohol variables. The genotype in the box refers to the rs738409 SNP. The ratio of the genotypes accurately classified over those wrongly classified is provided for each genotype in brackets.

Decision tree developed fixing the rs430397 A/A and G/A genotypes

This analysis selected the age, sex and alcohol variables. The genotype in the box refers to the rs738409 SNP. The ratio of the genotypes accurately classified over those wrongly classified is provided for each genotype in brackets.

DISCUSSION

The high variability of HCC incidence worldwide undoubtedly relates to differences in the distribution of environmental risk factors and most likely to variations in genetic susceptibilities between ethnic groups [24]. Outcomes in patients with HCC are critically dependent on early detection and diagnosis and hence the efficacy of public health strategies and screening programs [5]. The success of these programs, in turn, depends on the availability of validated, predictive markers with high sensitivity and specificity. In the present study, two SNPs, rs430397 in GRP78 and rs738409 in PNPLA3, were shown to be significantly associated with the risk of developing HCC in a Sicilian population. Further the possibility that these risk-associated genetic variants could be used to prediction the development of HCC on an individual patient basis was explored, using a machine learning technique, with promising results. Rs430397 lies in the fifth intron of GRP78. It has been associated with HCC risk in Chinese with HBV infection [10, 11] but does not appear to have been studied in European populations previously. As a non-protein-coding SNP, it could influence gene/protein function by altering gene expression but there is no direct evidence, to date, that this variant has functional effects. However, it does not lie in a GRP78 gene region associated with high transcriptional activity [25] nor in a CpG island associated with epigenetic mechanisms of gene silencing (T. Mazza: personal communication October 2016). Physiologically the GRP78 protein acts as a molecular chaperone, which is activated by endoplasmic reticulum stress [26] and is involved in intracellular calcium ion homeostasis [27]. It has also been reported to sustain cell survival, to inhibit apoptosis and to promote the invasion and metastasis of HCC cells in vitro [28-31]. However, the precise role of GRP78 in the development of cancer is still not clear [32, 33]. Rs738409 lies in the third exon of PNPLA3 and encodes a nonsynonymous alteration in the protein sequence (Ile148Met). This SNP came to prominence when identified as a risk factor for the progression of non-alcohol related fatty liver disease [16] and the development of alcohol-related cirrhosis [17]. Subsequently, the risk allele of rs738409 was shown to be associated with the development of HCC in patients of European descent with established cirrhosis [20]. Rs738409 has also been associated with the development of HCC in East Asian populations [34, 35]. The risk allele of rs738409 has also been studied in relation to HCV-related liver injury, although associations are less consistent [36, 37]. The results of the present study show that the rs738409:G allele is a significant risk for HCC in the Sicilian population. The fact that the strength of the association was increased in the subgroup with HCV-related cirrhosis with an effect size that exceeds that in many other studies is of interest but has to be weighed against the fact that these individuals comprised almost 85% of the study population. Despite the substantial genetic evidence implicating rs738409 and PNPLA3 with cirrhosis and HCC of different aetiologies, the function of the PNPLA3 protein remains uncertain as does the effect of the Ile148Met substitution. The 148Met risk allele appears to promote intracellular triglyceride retention [38] but the functional changes that lead to the development of significant liver damage and HCC remain to be established. Of interest the association between rs738409 and liver disease progression appears to be independent of the severity of liver fat accumulation [20, 39]. Further, the functional effects of this variant may directly or indirectly regulate the release of molecules involved in inflammation and fibrogenesis as intercellular adhesion molecule 1 and adiponectin [40-43]. The MAF of the rs738409 variant in the Sicilian control population utilized in the present study was higher than expected when compared with an ancestrally appropriate European reference population, e.g. the Toscani from Italy [23] (30% cf. 23%). This difference in allele frequency could reflect genetic isolation of the population of Sicily. However, a recent study has shown that Sicilians are genetically similar to mainland Italians from the adjacent regions [44]. Another potential explanation for this observation could be cryptic underlying population stratification, which may have arisen due to the use of blood-donor controls. Despite this, similar blood-donor controls are used in the Wellcome Trust Case-Control consortium cohort [45] with little evidence to suggest significant population stratification in their analyses. There was no evidence, in the present study, of an epistatic interaction between the GRP78 and PNPLA3 variants in relation to HCC risk. In addition there were no significant associations between either variant and any clinical features or the results of any of the laboratory investigation. However, combinations of these various attributes together with the rs430397 and rs738409 genotypes were used to produce a model, graphically displayed as a decision tree, which could be useful for predicting subjects at risk for developing HCC, at least within this study population. The best prediction model used only age, sex and alcohol as the additional required variables and was represented by a decision tree with a MCR of 17.0%. In conclusion: rs430397 in GRP78 and rs738409 in PNPLA3 are risk factors for the development of HCC in a Southern Italian population of cases with predominantly HCV-related cirrhosis. Use of a machine-learning approach allowed development of a prediction model incorporating phenotypic, clinical and genotypic variables. This computational approach needs to be further explored and the predictions independently validated. If confirmed, this approach could be used to identify individuals at risk at an early stage thereby facilitating monitoring and, when required, early intervention.

PATIENTS AND METHODS

Study populations

The 170 HCC cases were enrolled at the Department of Internal Medicine and Medical Specialties of the Policlinico Hospital, Palermo, Italy. All had been born in Sicily and continued to reside there. The aetiology of the liver disease was determined using historical, clinical, laboratory, imaging and histological information. The diagnosis of cirrhosis and HCC were made based on previously reported criteria [46], and international guidelines [47]. In the majority of instances the diagnosis of cirrhosis was based on historical, clinical, laboratory and radiological variables; histological confirmation was available in a minority from liver biopsy material obtained via the percutaneous route (Table 2). The diagnosis of HCC was based on historical, clinical, and laboratory variables together with, as recommended, multimodal imaging (Table 3). The 304 healthy blood donors, who acted as controls, were recruited at the Azienda di Rilievo Nazionale ad Alta Specialiazzione (A.R.N.A.S.) Civico Hospital of Palermo, Italy. Controls were only included if they were born in and continued to reside in Sicily; were aged > 30 years and in line with International guidelines [48, 49] were negative for HBsAg, anti-HCV and anti HIV antibodies and had normal routine blood test results. All included cases and controls provided written informed consent. This research was approved by the Ethics committee of the Policlinico Hospital (Palermo, Italy).

DNA extraction and genotyping

Genomic DNA was extracted from whole blood using the WizardGenomic DNA Purification Kit (Promega). DNA quality was assessed using gel electrophoresis (0.8% agarose gel; 5 volts/cm for 1 hour; 1× Tris-borate-EDTA (TBE) buffer; 100 bp and 1kb DNA Ladder (Promega, UK). Genotyping for rs430397 in GRP78 and rs738409 in PNPLA3 was performed using the K-Biosciences Competitive Allele Specific PCR (LGC Genomics, Hoddesdon, UK) platform with amplification and detection undertaken using a LightCycler® 480 real-time PCR system (Roche Molecular Diagnostics, Burgess Hill, UK). Genotype calling was performed automatically using proprietary software with minor manual editing of genotype calls. Approximately 12% of samples, randomly selected a priori, were genotyped in duplicate to ensure consistent genotype calling. The primers used for KASPar genotyping are detailed in Supplementary Table 1.

Statistical analysis

Genetic analysis

Tests for genetic association, missingness, deviation from Hardy-Weinberg equilibrium and epistasis were performed using PLINK (version 1.9) [50]. Genetic association analyses were performed using logistic regression utilizing additive, dominant and recessive models when comparing HCC cases and controls. Tests for association between demographic covariates were performed under an additive model using the Fisher's exact test to assess significance. Statistical analyses were performed in R [51].

Prediction modelling

A two-step analysis comprising of variable selection and decision tree construction was performed using a machine learning technique to establish a rule for predicting phenotypes starting from the genotypes of both the rs430397 and rs738409 variants. In the first step the variables to be used in the second step were selected utilizing a stepwise search, which performs a greedy forward or backward search through the space of HCC case characteristics or attributes. The selection is based on a decision tree classifier for estimating the accuracy of the chosen variable subset and is stopped when the addition/deletion of any remaining attribute resulted in a decrease in evaluation. The second step involved the construction of a tree-like graph or model of decisions based on the previously selected variables. This model exhibits a flowchart-like structure in which each internal node represents a ‘test’ on an attribute, each branch represents the outcome of the test and each leaf node represents a class label. The paths from root to leaves represent the classification rules. The evaluation of the classifier is based on the overall misclassification rate (MCR); the lower the MCR the better the prediction modelling. Both steps were performed using the RWeka package (R-3.2.3 software).
  47 in total

Review 1.  Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential.

Authors:  Amy S Lee
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

2.  High Expression of GRP78 Promotes Invasion and Metastases in Patients with Esophageal Squamous Cell Carcinoma.

Authors:  Guohong Zhao; Jianqin Kang; Kai Jiao; Guanghui Xu; Lei Yang; Shanhong Tang; Hui Zhang; Ying Wang; Yongzhan Nie; Kaichun Wu; Daiming Fan; Hongbo Zhang; Dexin Zhang
Journal:  Dig Dis Sci       Date:  2015-05-15       Impact factor: 3.199

3.  Glucose-regulated protein 78 (GRP78) regulates colon cancer metastasis through EMT biomarkers and the NRF-2/HO-1 pathway.

Authors:  Yu-Jia Chang; Wei-Yu Chen; Chien-Yu Huang; Hui-Hsiung Liu; Po-Li Wei
Journal:  Tumour Biol       Date:  2014-11-28

4.  Hepatocellular carcinoma: comparison of two different periods at the same center.

Authors:  Maurizio Soresi; Emanuele La Spada; Lydia Giannitrapani; Elisa Campagna; Valeria Di Gesaro; Walter Granà; Luigi Sandonato; Giuseppe Brancatelli; Giuseppe Rotolo; Andrea Affronti; Salvatore Messina; Giuseppe Montalto
Journal:  Eur J Intern Med       Date:  2010-01-13       Impact factor: 4.487

5.  Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment.

Authors:  Yan Liu; Felicia Wu
Journal:  Environ Health Perspect       Date:  2010-02-19       Impact factor: 9.031

6.  The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls.

Authors:  Luca Valenti; Raffaela Rametta; Massimiliano Ruscica; Paola Dongiovanni; Liliana Steffani; Benedetta Maria Motta; Elena Canavesi; Anna Ludovica Fracanzani; Enrico Mozzi; Giancarlo Roviaro; Paolo Magni; Silvia Fargion
Journal:  BMC Gastroenterol       Date:  2012-08-16       Impact factor: 3.067

7.  An intronic variant in the GRP78, a stress-associated gene, improves prediction for liver cirrhosis in persistent HBV carriers.

Authors:  Xiao Zhu; Lianzhou Chen; Wenguo Fan; Marie C M Lin; Linwei Tian; Min Wang; Sheng Lin; Zifeng Wang; Jinfang Zhang; Jinlong Wang; Hong Yao; Hsiangfu Kung; Dongpei Li
Journal:  PLoS One       Date:  2011-07-14       Impact factor: 3.240

8.  PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients.

Authors:  Kazunori Nakaoka; Senju Hashimoto; Naoto Kawabe; Yoshifumi Nitta; Michihito Murao; Takuji Nakano; Hiroaki Shimazaki; Toshiki Kan; Yuka Takagawa; Masashi Ohki; Takamitsu Kurashita; Tomoki Takamura; Toru Nishikawa; Naohiro Ichino; Keisuke Osakabe; Kentaro Yoshioka
Journal:  Springerplus       Date:  2015-02-13

9.  Polymorphisms of glucose-regulated protein 78 and risk of colorectal cancer: a case-control study in southwest China.

Authors:  Dan Zhang; Bin Zhou; Yuan Li; Mojin Wang; Cun Wang; Zongguang Zhou; Xiaofeng Sun
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

10.  GRP78 enhances the glutamine metabolism to support cell survival from glucose deficiency by modulating the β-catenin signaling.

Authors:  Zongwei Li; Yingying Wang; Haili Wu; Lichao Zhang; Peng Yang; Zhuoyu Li
Journal:  Oncotarget       Date:  2014-07-30
View more
  5 in total

Review 1.  Nonalcoholic fatty liver disease and hepatocellular carcinoma.

Authors:  Stephanie Klein; Jean-François Dufour
Journal:  Hepat Oncol       Date:  2017-10-30

2.  Chaperone-mediated autophagy compensates for impaired macroautophagy in the cirrhotic liver to promote hepatocellular carcinoma.

Authors:  Srinivas Chava; Christine Lee; Yucel Aydin; Partha K Chandra; Asha Dash; Milad Chedid; Swan N Thung; Krzysztof Moroz; Tong Wu; Nabeen C Nayak; Srikanta Dash
Journal:  Oncotarget       Date:  2017-06-20

3.  Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients.

Authors:  Carla De Benedittis; Mattia Bellan; Martina Crevola; Elena Boin; Matteo Nazzareno Barbaglia; Venkata Ramana Mallela; Paolo Ravanini; Elisa Ceriani; Stefano Fangazio; Pier Paolo Sainaghi; Michela Emma Burlone; Rosalba Minisini; Mario Pirisi
Journal:  Gastroenterol Res Pract       Date:  2020-04-24       Impact factor: 2.260

4.  The Circulating GRP78/BiP Is a Marker of Metabolic Diseases and Atherosclerosis: Bringing Endoplasmic Reticulum Stress into the Clinical Scenario.

Authors:  Josefa Girona; Cèlia Rodríguez-Borjabad; Daiana Ibarretxe; Joan-Carles Vallvé; Raimon Ferré; Mercedes Heras; Ricardo Rodríguez-Calvo; Sandra Guaita-Esteruelas; Neus Martínez-Micaelo; Núria Plana; Lluís Masana
Journal:  J Clin Med       Date:  2019-10-26       Impact factor: 4.241

Review 5.  Chaperone-Mediated Autophagy in the Liver: Good or Bad?

Authors:  Srikanta Dash; Yucel Aydin; Krzysztof Moroz
Journal:  Cells       Date:  2019-10-24       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.